Microsoft and Novartis have announced that they will be collaborating to address the challenges in the process of drug development. Through this collaboration, the companies plan to bring massive changes to every phase of drug development process by combining Microsoft’s AI technology and Novartis’ deep life sciences expertise.
The strategic collaboration will see the two companies commit to multi-year research and development effort. The companies will be establishing a lab to put these efforts into effect.
The effort will see the integration of Novartis datasets with Microsoft’s advanced AI solutions which will provide the researchers with capabilities to tackle the new challenges in medicine. Further, the efforts will be also focusing on taking on computational challenges in life sciences including generative chemistry, image segmentation, gene therapies and more.
Microsoft CEO, Satya Nadella said: “Our strategic alliance will combine Novartis' life sciences expertise with the power of Azure and Microsoft AI. Together, we aim to address some of the biggest challenges facing the life sciences industry today and bring AI capabilities to every Novartis employee so they can unlock new insights as they work to discover new medicines and reduce patient costs.”
The two companies will also work together to develop and apply next-gen AI processes and platforms to support future programs.
Microsoft and Aruba collaborate to enhance cybersecurity offerings
Microsoft and Telkomsel join hands in Indonesia
Attivo Networks joins hands with Microsoft Azure
Microsoft launches 100X100X100 program for B2B SaaS startups
Microsoft struck a cloud partnership deal with Reliance
© 2020 CIO Bulletin. All rights reserved.